SAMs are also present in human sympathetic ganglia, possessing the same machinery (MAOA, SLC6A2), suggesting the mechanism is evolutionarily conserved, and therefore could be a viable anti-obesity therapeutic target. Here, SLC6A2 is linked to obesity due to melanocortin 4 receptor deficiency.